Compare EVR & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVR | SNN |
|---|---|---|
| Founded | 1995 | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Managers | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7B | 12.3B |
| IPO Year | 2006 | 2002 |
| Metric | EVR | SNN |
|---|---|---|
| Price | $290.79 | $29.35 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 2 |
| Target Price | ★ $359.38 | $36.25 |
| AVG Volume (30 Days) | 564.6K | ★ 1.4M |
| Earning Date | 04-29-2026 | 03-16-2026 |
| Dividend Yield | 1.04% | ★ 2.48% |
| EPS Growth | ★ 54.74 | N/A |
| EPS | ★ 9.56 | N/A |
| Revenue | ★ $3,880,084,000.00 | N/A |
| Revenue This Year | $22.69 | $8.58 |
| Revenue Next Year | $13.31 | $5.60 |
| P/E Ratio | ★ $30.29 | $64.97 |
| Revenue Growth | ★ 29.49 | N/A |
| 52 Week Low | $265.87 | $28.56 |
| 52 Week High | $388.71 | $38.79 |
| Indicator | EVR | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 35.06 | 42.85 |
| Support Level | $265.87 | $28.56 |
| Resistance Level | $353.60 | $30.52 |
| Average True Range (ATR) | 8.86 | 0.38 |
| MACD | -0.58 | -0.09 |
| Stochastic Oscillator | 9.79 | 33.14 |
Evercore is a leading independent investment banking advisory firm that generates most of its revenue through merger and acquisition and restructuring advisory services, with much smaller capital raising, equities trading, and investment management businesses. Founded in 1995, it has built a reputation for advising on some of the world's largest and most complex transactions. Evercore operates globally, with a strong presence in the US and Europe, serving corporations, financial sponsors, and government clients. Its business model emphasizes high-touch, conflict-free advice rather than balance sheet lending, allowing it to compete with larger bulge-bracket banks.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 40% of the UK-based firm's revenue comes from orthopedic products, and another 31% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the US, just over 30% is from other developed markets, and emerging markets account for the remainder.